AstraZeneca-backed Entasis Therapeutics joins the IPO class of 2018 with a weak debut price
Entasis Therapeutics has made it to Nasdaq.
The antibiotics group — a spinout from AstraZeneca — had a disappointing debut, pricing shares at $15 apiece …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
